Posting of Shareholder Circular

23 June 2016

Epistem Holdings plc ("Epistem" or the "Company")

Posting of Shareholder Circular

23 June 2016: Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, confirms that further to the announcement made earlier today, a Circular has been published and will be posted to shareholders today in relation to the proposed Placing of 8,125,000 Ordinary Shares at 80 pence per share and agreement to amend and restate the GHIF Bond. The circular contains the notice convening the General Meeting to be held at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH on 11 July 2016 at 10.00 a.m.

A copy of the Circular will shortly be available on the Company's website at the following URL: http://www.epistem.co.uk/.

For further details please contact:

Notes to Editors

About Epistem

Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test has been launched in India. Further details can be found at: www.epistem.co.uk  and www.genedrive.com